Medcura develops biopolymer-based hemostatic technologies and surgical bleeding-control products, centered on a proprietary hydrophobically modified chitosan platform. Its flagship LifeGel flowable gel received FDA Breakthrough Device Designation in 2022 for procedures where swelling cannot be tolerated, while the company’s scientists and engineers continue developing the platform in formats such as films, powders and gauze. Based in Riverdale, Maryland, Medcura works with surgeons and healthcare professionals throughout product development.
FDA Breakthrough Device Designation
compliance_program
FDA Clearance K143466
registration
FDA Clearance K172010
registration
FDA Clearance K180152
registration
FDA Clearance K182811
registration
FDA Clearance K192667
registration